ClinicalTrials.gg
CompletedNCT01007435Updated Jul 26, 2017Results posted

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of Tocilizumab and Placebo to tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 236 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
6th of 110
1,162 · median 97
Started
2009
with 9 others
Phase 3
65 of 110
none open now
Registered
26th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 10 that started in 2009, is one of 65 in phase 3, and was the 26th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This randomized, double-blind, parallel group study will assess the safety, disease remission, and prevention of structural joint damage in patients with early moderate to severe rheumatoid arthritis treated with tocilizumab as monotherapy or in combination with methotrexate, versus methotrexate alone. Patients will be randomized to receive either (A) tocilizumab (8 mg/kg iv every 4 weeks) plus placebo, (B) tocilizumab (8 mg/kg iv every 4 weeks) plus methotrexate (7.5-20 mg po weekly), (C) tocilizumab (4 mg/kg iv every 4 weeks) plus methotrexate (7.5-20 mg po weekly), or (D) placebo plus methotrexate (7.5-20 mg po weekly). Patients in groups C and D who have not achieved low disease activity at week 52 can receive tocilizumab 8 mg/kg iv every 4 weeks. Anticipated time on study treatment is 104 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 18 years of age.
  • Rheumatoid arthritis of ≤ 2 years duration.
  • Disease Activity Score 28 (DAS28) > 3.2.
  • Swollen joint count (SJC) ≥ 4 of 66 joints, tender joint count (TJC) ≥ 6 of 68 joints.
  • Rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) positive (if RF and anti-CCP negative > 1 erosion required at screening).
  • Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h or C-reactive protein (CRP) ≥ 10 mg/L at screening.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with tocilizumab.
  • Previous treatment with methotrexate or biologic agent.
  • Rheumatic disease other than rheumatoid arthritis (RA).
  • History of or current inflammatory joint disease other than RA.
  • Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in RA.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,162 participants (actual)

Study arms

  • Experimental
    (A) Tocilizumab 8 mg/kg + placebo to methotrexate

    Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.

    Drug: Tocilizumab · Drug: Placebo to methotrexate

  • Experimental
    (B) Tocilizumab 8 mg/kg + methotrexate

    Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.

    Drug: Tocilizumab · Drug: Methotrexate

  • Experimental
    (C) Tocilizumab 4 mg/kg + methotrexate

    Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.

    Drug: Tocilizumab · Drug: Methotrexate

  • Active comparator
    (D) Placebo to tocilizumab + methotrexate

    Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.

    Drug: Placebo to tocilizumab · Drug: Methotrexate

Interventions

  • Tocilizumab was supplied in vials.

    Also known as: RoActemra, Actemra

  • DrugPlacebo to tocilizumab

    Placebo to tocilizumab was supplied in vials.

  • Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.

  • DrugPlacebo to methotrexate

    Patients received placebo to methotrexate orally once a week.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24

    A participant has a DAS28 remission response if their DAS28 \< 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52

    Time frame: Week 52

  2. Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52

    Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.

    Time frame: Baseline to Weeks 24 and 52

  3. Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52

    The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

    Time frame: Baseline to Week 52

  4. Change From Baseline in Modified Sharp Erosion Score at Week 52

    Time frame: Baseline to Week 52

  5. Change From Baseline in Sharp Joint Space Narrowing Score at Week 52

    Time frame: Baseline to Week 52

  6. Percentage of Participants With a Major Clinical Response at Week 52

    A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.

    Time frame: Baseline to Week 52

  7. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52

    The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

    Time frame: Baseline to Weeks 24 and 52

  8. Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52

    The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.

    Time frame: Baseline to Weeks 24 and 52

07

Results

Posted Jul 12, 2013

Participant flow

Participant flow — Overall Study
MilestonePlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Started289290291292
Completed226231227236
Not completed63596456
Withdrew: Adverse event16254731
Withdrew: Death2421
Withdrew: Insufficient therapeutic response21729
Withdrew: Violation of selection criteria at entry3520
Withdrew: Other protocol violation2010
Withdrew: Refused treatment131358
Withdrew: Failure to return5436
Withdrew: Reason not specified1121

Outcome measures

PrimaryPercentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24

A participant has a DAS28 remission response if their DAS28 \< 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24
Percentage of participantsPlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 2415.0 (10.9 to 19.1)31.9 (26.6 to 37.3)44.8 (39.1 to 50.6)38.7 (33.1 to 44.3)
Statistical analysis
  • Placebo to Tocilizumab + Methotrexate vs Tocilizumab 8 mg/kg + Methotrexate · Regression, Logistic · p = <0.0001 (A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons.) · Odds ratio (or): 4.77 · 95% CI 3.19 to 7.14Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to "non-responder".
  • Placebo to Tocilizumab + Methotrexate vs Tocilizumab 8 mg/kg + Placebo to Methotrexate · Regression, Logistic · p = <0.0001 (A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons.) · Odds ratio (or): 3.70 · 95% CI 2.47 to 5.55Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to "non-responder".
  • Placebo to Tocilizumab + Methotrexate vs Tocilizumab 4 mg/kg + Methotrexate · Regression, Logistic · p = <0.0001 (A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons. This comparison came after the break in statistical hierarchy.) · Odds ratio (or): 2.72 · 95% CI 1.80 to 4.11Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to "non-responder".
SecondaryPercentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52
Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52
Percentage of participantsPlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 5219.534.049.039.4
SecondaryPercentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52

Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "no disease activity" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum disease activity"; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line "no pain" and the extreme right end "unbearable pain"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.

Time frame:
Baseline to Weeks 24 and 52
Reported as:
Number · Percentage of participants
Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52
Percentage of participantsPlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Week 24: ACR 2065.273.674.570.2
Week 24: ACR 5043.247.956.947.6
Week 24: ACR 7025.434.738.630.1
Week 52: ACR 2057.162.867.263.0
Week 52: ACR 5040.852.455.949.3
Week 52: ACR 7028.937.243.136.0
SecondaryChange From Baseline in Modified Total Sharp Score (mTSS) at Week 52

The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52
Units on a scalePlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 521.14 ± 4.2970.42 ± 2.9290.08 ± 2.0900.26 ± 1.876
SecondaryChange From Baseline in Modified Sharp Erosion Score at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Modified Sharp Erosion Score at Week 52
Units on a scalePlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Change From Baseline in Modified Sharp Erosion Score at Week 520.63 ± 2.5560.25 ± 1.6860.05 ± 1.7360.15 ± 1.544
SecondaryChange From Baseline in Sharp Joint Space Narrowing Score at Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Sharp Joint Space Narrowing Score at Week 52
Units on a scalePlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Change From Baseline in Sharp Joint Space Narrowing Score at Week 520.51 ± 2.3620.17 ± 1.6450.03 ± 0.7510.11 ± 1.046
SecondaryPercentage of Participants With a Major Clinical Response at Week 52

A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a Major Clinical Response at Week 52
Percentage of participantsPlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Percentage of Participants With a Major Clinical Response at Week 5216223122
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52

The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

Time frame:
Baseline to Weeks 24 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52
Units on a scalePlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Week 24 (n=246, 255, 250, 265)-0.71 ± 0.718-0.92 ± 0.736-0.91 ± 0.695-0.82 ± 0.739
Week 52 (n=214, 227, 228, 230)-0.76 ± 0.800-1.00 ± 0.795-0.97 ± 0.700-0.87 ± 0.776
SecondaryChange From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52

The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.

Time frame:
Baseline to Weeks 24 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52
Units on a scalePlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Week 24 (n=237, 247, 246, 255)9.35 ± 9.76311.33 ± 9.28212.13 ± 9.26310.75 ± 10.055
Week 52 (n=204, 225, 221, 224)10.72 ± 10.38912.27 ± 10.50913.52 ± 9.84811.73 ± 10.691

Adverse events

Collected over Adverse events were reported from Baseline through Week 52.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo to Tocilizumab + Methotrexate—24/282 (8.5%)177/282 (62.8%)
Tocilizumab 4 mg/kg + Methotrexate—29/289 (10%)182/289 (63%)
Tocilizumab 8 mg/kg + Methotrexate—31/290 (10.7%)201/290 (69.3%)
Tocilizumab 8 mg/kg + Placebo to Methotrexate—25/292 (8.6%)163/292 (55.8%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventPlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
PneumoniaInfections and infestations1/2824/2891/2901/292
PregnancyPregnancy, puerperium and perinatal conditions0/2820/2892/2904/292
AppendicitisInfections and infestations0/2820/2893/2900/292
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/2820/2890/2900/292
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2822/2890/2900/292
CellulitisInfections and infestations0/2821/2891/2902/292
AsthmaRespiratory, thoracic and mediastinal disorders0/2820/2890/2902/292
BronchopneumoniaInfections and infestations1/2821/2891/2900/292
Appendicitis perforatedInfections and infestations1/2820/2890/2900/292
Pneumonia influenzalInfections and infestations1/2820/2890/2900/292
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlacebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to Methotrexate
Alanine aminotransferase increasedInvestigations29/28239/28955/29022/292
NauseaGastrointestinal disorders46/28241/28943/29019/292
Upper respiratory tract infectionInfections and infestations40/28237/28930/29039/292
NasopharyngitisInfections and infestations38/28240/28928/29027/292
Transaminases increasedInvestigations23/28235/28940/29022/292
HypertensionVascular disorders21/28216/28923/29025/292
Rheumatoid arthritisMusculoskeletal and connective tissue disorders21/2829/28916/29010/292
HeadacheNervous system disorders12/28220/28918/29020/292
BronchitisInfections and infestations6/28218/28920/2908/292
DiarrhoeaGastrointestinal disorders18/28216/28919/29018/292

Baseline characteristics

Baseline Characteristics were based on the intent-to-treat (ITT) population. Five of 1162 randomized patients (2 placebo + methotrexate, 2 tocilizumab 4 mg/kg + methotrexate, 1 tocilizumab 8 mg/kg + methotrexate) did not receive any study treatment and were excluded from all analysis populations. The ITT population therefore included 1157 patients.

Age, Continuous
Age, Continuous(years)Placebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to MethotrexateTotal
Mean49.6 ± 13.1051.2 ± 13.8449.5 ± 13.7049.9 ± 13.2250.1 ± 13.47
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to Tocilizumab + MethotrexateTocilizumab 4 mg/kg + MethotrexateTocilizumab 8 mg/kg + MethotrexateTocilizumab 8 mg/kg + Placebo to MethotrexateTotal
Female229228228219904
Male58606273253
08

Study locations

236 sites
  • Pinnacle Research Group; Llc, Central
    Anniston, Alabama 36207, United States
  • Rheumatology Associates of North Alabama
    Huntsville, Alabama 35801, United States
  • Clnical & Translational Reseach Center for Alabama, PC
    Tuscaloosa, Alabama 35406, United States
  • Arthrocare, Arthritis Care and Research, P.C.
    Mesa, Arizona 85208, United States
  • Sun Valley Arthritis Center
    Peoria, Arizona 85381, United States
  • Talbert Medical Group
    Huntington Beach, California 92646, United States
  • Uni of California - San Diego; Division of Rheumatology
    La Jolla, California 92037, United States
  • Valerius Medical Group & Research Ctr of Greater Long Beach
    Los Alamitos, California 90720, United States
  • Sharp Rees-Stealy Medical Group
    San Diego, California 92101, United States
  • San Diego Arthritis Med Clnc
    San Diego, California 92108, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230-7127, United States
  • Joao Nascimento
    Bridgeport, Connecticut 06606, United States
  • New England Research Associates
    Trumbull, Connecticut 06611, United States
  • Arthritis/Osteoporosis Treatment Center
    Orange Park, Florida 32073, United States
  • Arthritis Center Palm Harbor
    Palm Harbor, Florida 34684, United States
  • Arthritis Rsrch of Florida, Inc.
    Palm Harbor, Florida 34684, United States
  • Burnette & Silverfield, MDS
    Tampa, Florida 33614, United States
  • Quad City Rheumatology, Sc
    Moline, Illinois 61265, United States
  • Illinois Bone & Joint Inst.
    Morton Grove, Illinois 60053, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Physician'S Clinic of Iowa
    Cedar Rapids, Iowa 52401, United States
  • Via Christi Clinic, PA
    Wichita, Kansas 67208, United States
  • Baton Rouge Clinic, Amc
    Baton Rouge, Louisiana 70808, United States
  • Osteoporosis & Clinical Trials Center
    Cumberland, Maryland 21502, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01605, United States
  • Borgess Rheumatology
    Kalamazoo, Michigan 49009, United States
  • Fiechtner Research Inc
    Lansing, Michigan 48910, United States
  • Harbor Arthritis Center
    Petoskey, Michigan 49770, United States
  • Park Nicollet Inst. ; Rtrc
    Minneapolis, Minnesota 55416, United States
  • Jackson Arthritis Clinic
    Flowood, Mississippi 39232, United States
  • North Mississippi Medical Ctr; Internal Medicine Associates
    Tupelo, Mississippi 38802, United States
  • Depaul Medical Group-SSM Healthcare
    Florissant, Missouri 63031, United States
  • Dartmouth-Hitchcock Medical Center, Rheumatology 5C
    Lebanon, New Hampshire 03756, United States
  • NJP Clinical Research
    Clifton, New Jersey 07012, United States
  • Mark Fisher Md, Facr, Llc
    Haddon Heights, New Jersey 08035, United States
  • Albuquerque Center For Rheumatology
    Albuquerque, New Mexico 87102, United States
  • Arthritis and Osteoporosis Associates of New Mexico
    Las Cruces, New Mexico 88011, United States
  • Arthritis Health Associates; Clinical Research
    Syracuse, New York 13210, United States
  • Asheville Arthritis & Osteoporosis Center, PA
    Asheville, North Carolina 28803, United States
  • Durham Rheumatology
    Durham, North Carolina 27704, United States
  • Ohio State University; Dept of Immunology
    Columbus, Ohio 43210, United States
  • Southwest Rheumatology & Research Group, LLC
    Middleburg Heights, Ohio 44130, United States
  • Health Research of Oklahoma, Llc
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States
  • East Penn Rheumatology Associates, Pc
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading
    Wyomissing, Pennsylvania 19610, United States
  • Piedmont Arthritis Clinic
    Greenville, South Carolina 29601, United States
  • Amarillo Center For Clinical Research
    Amarillo, Texas 79124, United States
  • Accurate Clinical Research
    Houston, Texas 77034, United States
  • Houston Inst. For Clinical Research
    Houston, Texas 77074, United States
  • Arthritis & Osteoporosis Associates, LLP
    Lubbock, Texas 79424, United States
  • Texas Arthritis Research Center; Center for Arthritis & Rheumatic Diseases
    San Antonio, Texas 78217, United States
  • Texas Research Center
    Sugar Land, Texas 77479, United States
  • Arthritis & Osteoporosis Clinic
    Waco, Texas 76710, United States
  • Arthritis Northwest, Spokane
    Spokane, Washington 99204, United States
  • Tacoma Center For Arthritis Research
    Tacoma, Washington 98405, United States
  • Wenatchee Valley Hospital & Clinics
    Wenatchee, Washington 98801, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Inst. de Rehabilitacion Psicofisica; Reumathology
    Buenos Aires, C1428DQG, Argentina
  • Caici; Rheumatology
    Rosario, S2000PBJ, Argentina
  • Centro Medico Privado de Reumatologia; Reumathology
    San Miguel, T4000AXL, Argentina
  • Royal Prince Alfred Hospital; Rheumatology
    Camperdown, New South Wales 2050, Australia
  • Sunshine Coast Rheumatology Research Unit
    Maroochydore, Queensland 4558, Australia
  • Queen Elizabeth Hospital; Rheumatology
    Woodville, South Australia 5011, Australia
  • Menzies Research Institute
    Hobart, Tasmania 7100, Australia
  • Cabrini Medical Centre; Rheumatology
    Malvern, Victoria 3144, Australia
  • Worthing Hospital
    Murdoch, Western Australia 6150, Australia
  • Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin
    Innsbruck, 6020, Austria
  • Kaiser Franz Josef Spital; Ii. Medizinische Abt.
    Wien, 1100, Austria
  • Krankenhaus der stadt wien hietzing; ii. Med. Abt. / zentrum für rheumatologie
    Wien, 1130, Austria
  • Centro Internacional de Pesquisa; Reumatologia
    Goiania, GO 74110010, Brazil
  • Hospital das Clinicas - UFG;Reumatologia
    Goiania, GO 74653-050, Brazil
  • Centro Mineiro de Pesquisa - CMIP
    Juiz de Fora, MG 36036-330, Brazil
  • Centro de Estudos em Terapias Inovadoras - CETI
    Curtiba, PR 80030-110, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Hospital e Maternidade Celso Pierro - PUCCamp; Reumatologia
    Campinas, SP 13059-900, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP; Reumatologia
    Sao Paulo, SP 04026-000, Brazil
  • Centro Paulista de Investigacao Clinica - CEPIC
    Sao Paulo, SP 04266-010, Brazil
  • Arthritis Research Centre
    Vancouver, British Columbia V5Z 1L7, Canada
  • Laurel Medical Clinic
    Vancouver, British Columbia V5Z 3Y1, Canada
  • Manitoba Clinic
    Winnipeg, Manitoba R3A 1M3, Canada
  • Nexus Clinical Research Centre
    St John's, Newfoundland and Labrador A1A 5E8, Canada
  • Dr. William G. Bensen Medicine Professional Corporation
    Hamilton, Ontario L8N 1Y2, Canada
  • K-W Musculoskeletal Research
    Kitchener, Ontario N2M 5N6, Canada
  • St. Joseph'S Health Care Centre; Rheumatology
    London, Ontario N6A 4V2, Canada
  • Rheumatology Research Associates
    Ottawa, Ontario K1H 1A2, Canada
  • Niagara Peninsula Arthritis Centre
    St. Catharines, Ontario L2N 7E4, Canada
  • Hopital Maisonneuve- Rosemont; Rheumatology
    Montreal, Quebec H1T 2M4, Canada
  • Institut de Rhumatologie de Montreal
    Montreal, Quebec H2L 1S6, Canada
  • Centre de Recherche Musculo-Squelettique
    Trois-rivieres, Quebec G8Z 1Y2, Canada
  • Saskatoon Osteoporosis Centre
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Centre Re Recherche Saint-Louis
    Quebec, G1W 4R4, Canada
  • China-Japan Friendship Hospital
    Beijing, 10029, China
  • General Hospital of Chinese PLA; Department of Hematology
    Beijing, 100853, China
  • The Third Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, 510630, China
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, 200127, China

Showing the first 100 of 236 sites across 36 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 Jul;76(7):1279-1284. doi: 10.1136/annrheumdis-2016-210561. Epub 2017 Apr 7. PubMed 28389552 ↗
  • Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun;75(6):1081-91. doi: 10.1136/annrheumdis-2015-207628. Epub 2015 Oct 28. PubMed 26511996 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in May 2012, 31 months.

Results were first posted in Jul 2013, 1 year 1 month after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2009
First posted
Nov 4, 2009
StartActual
Oct 31, 2009
Primary completionActual
May 31, 2012
CompletionActual
Jan 28, 2014
Results first posted
Jul 12, 2013
Last update
Jul 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01007435
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 4, 2009
Start date
Oct 31, 2009
Primary completion
May 31, 2012
Completion
Jan 28, 2014
Results posted
Jul 12, 2013
Last update
Jul 26, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Methotrexate

Start the discussion